BioMedTracker is featuring content from respected outside sources to augment its original report content. This article was originally published by IN VIVO, July/August 2015. IN VIVO is the premier strategic business resource for the biopharma, medtech, and diagnostics industries. For more information about IN VIVO, please visit IN VIVO here. There's a correlation between up-front payments and actual drug approval rates. First in a series of follow-ups to IN VIVO's 2014 study comparing/contrasting likelihood of approval and up-front payments on alliances, and the outcomes of relevant deals.

In this report, Amanda Micklus evaluates approximately 394 transactions that occurred during 2003-2011, including deals from Phase I to III candidates across seven therapeutic areas - cancer, cardiology, immune, infectious, metabolic, neurology, and respiratory. Deals included were restricted to those with a disclosed up-front value of at least $1 million.

Approximately 119 deals out of the 394 had been terminated but were included in the analysis. Of the 119, 22 deals produced an approved drug post-deal- termination.The drugs that were included were the ones that were part of the original deal terms and associated with that up-front payment.

BioMedTracker, Medtrack and PharmaProjects were used to determine the current phase of the drug.

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.